克羅諾斯集團因交易量激增而飆升

Cronos Group Inc.（NASDAQ：CRON）週二交易量異常強勁，共有 4,756,022 股易手，較前一交易日成交量激增 91%。該股收盤價為 2.67 美元，高於先前的收盤價 2.49 美元。

Cronos Group Shares Soar Amid Surge in Trading Volume

克羅諾斯集團股價因交易量激增而飆升

Cronos Group Inc. (NASDAQ: CRON), a prominent player in the cannabinoid industry, witnessed a notable surge in trading activity on Tuesday. The company's stock volume reached approximately 4,756,022 shares, representing a significant 91% increase from the previous session's volume of 2,487,493 shares. The stock closed the day at $2.67, up from its previous close of $2.49.

大麻素產業的知名企業克羅諾斯集團公司（納斯達克股票代碼：CRON）週二的交易活動顯著激增。該股成交量達到約4,756,022股，較前一交易日的2,487,493股大幅增加91%。該股當日收盤價為 2.67 美元，高於前一收盤價 2.49 美元。

Analyst Coverage

分析師報道

Bank of America recently upgraded its price target on Cronos Group shares, raising it from $1.78 to $2.00. However, the firm maintained an "underperform" rating for the company in a research note dated December 28th, 2023.

美國銀行最近上調了 Cronos Group 股票的目標股價，從 1.78 美元上調至 2.00 美元。然而，該公司在 2023 年 12 月 28 日的研究報告中維持該公司「表現不佳」的評級。

Stock Performance and Valuation

股票表現和估值

Cronos Group shares have gained 6.0% year-to-date. The company currently has a market capitalization of $1.01 billion, a P/E ratio of -13.89, and a beta of 1.13. Its 50-day moving average price stands at $2.14, while its 200-day moving average price is $2.05.

Cronos Group 股價今年迄今已上漲 6.0%。該公司目前市值為10.1億美元，市盈率為-13.89，貝塔值為1.13。其50天移動平均價格為2.14美元，200天移動平均價格為2.05美元。

Financial Results

財務業績

Cronos Group last reported its quarterly financial results on February 29th, 2023. The company posted a loss of $0.05 per share for the quarter. Revenue for the period amounted to $23.92 million, falling short of the consensus estimate of $25.15 million. Cronos Group's return on equity and net margin were negative, at -3.99% and -84.15%, respectively.

Cronos Group 上次於 2023 年 2 月 29 日公佈了季度財務業績。該公司公佈該季度每股虧損 0.05 美元。該期間收入為 2,392 萬美元，低於市場普遍預期的 2,515 萬美元。 Cronos Group的股本回報率和淨利潤率為負，分別為-3.99%和-84.15%。

Earnings Outlook

獲利展望

Analysts anticipate that Cronos Group Inc. will report a loss of $0.01 per share for the current fiscal year.

分析師預估 Cronos Group Inc. 本會計年度每股虧損 0.01 美元。

Institutional Ownership

機構所有權

Hedge funds and other institutional investors have recently adjusted their positions in Cronos Group. Chesapeake Capital Corp IL established a $25,000 stake in the company during the fourth quarter, while Cetera Investment Advisers acquired a $38,000 stake in the same period. Deutsche Bank AG significantly increased its holdings by 21,218.6%, purchasing 14,853 additional shares during the fourth quarter. Quantbot Technologies LP and Cetera Advisor Networks LLC initiated new positions in Cronos Group in the second and second quarters, respectively. Institutional investors collectively own 8.63% of the company's outstanding shares.

對沖基金和其他機構投資者最近調整了在克羅諾斯集團的部位。 Chesapeake Capital Corp IL 在第四季度購買了該公司 25,000 美元的股份，而 Cetera Investment Advisers 同期收購了 38,000 美元的股份。德意志銀行在第四季大幅增持 21,218.6%，額外購買了 14,853 股。 Quantbot Technologies LP 和 Cetera Advisor Networks LLC 分別於第二季和第二季在 Cronos Group 中設立了新職位。機構投資人合計持有該公司已發行股份的8.63%。

Company Profile

公司簡介

Cronos Group Inc. is engaged in the production and distribution of cannabinoid products. The company operates in the United States, cultivating, manufacturing, and marketing cannabis and cannabis-derived products for medical and adult-use markets. Additionally, it manufactures, markets, and distributes hemp-derived supplements and cosmetic products under the Lord Jones brand through various distribution channels.

Cronos Group Inc. 從事大麻素產品的生產和分銷。該公司在美國經營，為醫療和成人使用市場種植、製造和行銷大麻及大麻衍生產品。此外，它還透過各種分銷管道以 Lord Jones 品牌製造、行銷和分銷大麻衍生補充劑和化妝品。

Recommendations

建議

MarketBeat, a platform that tracks top-rated research analysts and their stock recommendations, has identified five companies that analysts are bullish on. Notably, Cronos Group is not included in this list of recommended stocks.

MarketBeat 是一個追蹤頂尖研究分析師及其股票推薦的平台，它已經確定了分析師看好的五家公司。值得注意的是，克羅諾斯集團並未包含在此推薦股票名單中。

Disclaimer

免責聲明

This article is for informational purposes only and should not be considered investment advice. Investors should conduct due diligence and consult with a financial professional before making any investment decisions.

本文僅供參考，不應視為投資建議。投資者在做出任何投資決定之前應進行盡職調查並諮詢金融專業人士。